• AstraZeneca’s Alexion unit set 16 presentations for the ASBMR meeting in Boston on Oct. 9-12, 2026.
• Phase III HICKORY results for efzimfotase alfa in adolescent and adult hypophosphatasia will be presented in the future.
• Data are positioned to support broader use in adult-onset disease, potentially reshaping care expectations while aiming to reduce treatment burden.
• Phase III CALYPSO skeletal findings for eneboparatide in chronic hypoparathyroidism are also scheduled for future presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.